Biolegend, 329920, Brilliant Violet 421™ anti-human CD279 (PD-1) Antibody, 100tests

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.
100tests
Verified Reactivity: Human
Reported Reactivity: African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA) Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA) Velu V, et al. 2007. J. Virol. 81:5819. (FA) Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA) Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity) Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Geetha H. Mylvaganam, Daniel Rios 2017. Proc Natl Acad Sci U S A. 114(8):1976-1981. PubMed Cheng DN, et al. 2023. Elife. 12:. PubMed Kim HS, et al. 2023. Front Cell Infect Microbiol. 13:1101291. PubMed Wang X, et al. 2023. Stem Cell Rev Rep. . PubMed Kim JH, et al. 2020. Sci Rep. 10:1835. PubMed Jiang W, et al. 2021. Sci Rep. 11:1864. PubMed Wei H, et al. 2022. Front Immunol. 13:1060695. PubMed Touizer E, et al. 2023. iScience. 26:105862. PubMed Wang P, et al. 2023. Front Immunol. 13:1104329. PubMed Statzu M, et al. 2023. Nat Microbiol. 8:299. PubMed Giles JR, et al. 2022. Immunity. 55:557. PubMed Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed Gibellini L, et al. 2020. EMBO Mol Med. 12:e13001. PubMed Mylvaganam G, et al. 2014. J Immunol. 193:4527. PubMed Claiborne DT, et al. 2019. PLoS Pathog. 15:e1007981. PubMed Whitney JB, et al. 2018. Nat Commun. 9:5429. PubMed Komech EA, et al. 2022. Front Immunol. 13:973243. PubMed Wu VH, et al. 2020. JCI Insight. 5:00. PubMed Nielsen CM, et al. 2021. Cell Reports Medicine. 2(3):100207. PubMed Mastelic-Gavillet B, et al. 2019. J Immunother Cancer. 7:257. PubMed Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed Parackova Z, et al. 2020. Sci Rep. 0.759027778. PubMed Goncharov MM, et al. 2022. Elife. 11:. PubMed AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed Calascibetta F, et al. 2016. J Virol. 90: 7541 - 7551. PubMed Gupta R, et al. 2022. Front Immunol. 13:886442. PubMed Wang Z, et al. 2021. Cell Mol Immunol. 18:2188. PubMed Eberhardt K, et al. 2015. Clin Infect Dis. 61: 1615 - 1623. PubMed Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed Lindesmith LC, et al. 2020. Cell Mol Gastroenterol Hepatol. 0.586805556. PubMed Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed Massafra V, et al. 2021. J Immunol. 207:493. PubMed Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed Cui J, et al. 2020. Cancers (Basel). 0.596527778. PubMed Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed Harper J, et al. 2022. J Clin Invest. . PubMed Juno JA, et al. 2020. Nat Med. 26:1428. PubMed Bergamaschi L, et al. 2021. Immunity. 54(6):1257-1275.e8. PubMed Kreutmair S, et al. 2021. Immunity. . PubMed Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed Minagawa A, et al. 2018. Cell Stem Cell. 1.548611111. PubMed van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed Miller IC, et al. 2021. Nature Biomedical Engineering. :. PubMed André P et al. 2018. Cell. 175(7):1731-1743 . PubMed Sayin I, et al. 2018. J Exp Med. 7:40286. PubMed Xu L, et al. 2021. Front Oncol. 11:686156. PubMed Naidoo KK, et al. 2020. PLoS One. 15:e0242448. PubMed Li L, et al. 2020. J Transl Med. 18:363. PubMed Seo IH, et al. 2021. Immune Netw. 21:e17. PubMed Minassian AM, et al. 2021. Med (N Y). 2:701. PubMed Buggert M, et al. 2014. J Immunol. 192:2099. PubMed Buggert M, et al. 2014. J Immunol. 192:4685. PubMed Cao J, et al. 2018. Nat Commun. 9:77. PubMed Lee SWL, et al. 2018. Front Immunol. 8:1064. PubMed Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed El Ahanidi H, et al. 2022. Front Oncol. 11:795242. PubMed Pacheco Y, et al. 2013. J Immunol. 191:2072. PubMed Ferrando-Martinez S, et al. 2018. J Clin Invest. 128:2089. PubMed Rutishauser L, et al. 2017. AIDS Res Hum Retroviruses . 10.1089/AID.2016.0324. PubMed Jung JH, et al. 2021. Nat Commun. 12:4043. PubMed Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed Zabaleta N, et al. 2021. Cell Host Microbe. :. PubMed Harper JL, et al. 2020. Nat Med. 519:26. PubMed Li C, et al. 2020. Immunity. 52(1):201-202. PubMed Routhu NK, et al. 2021. Immunity. 54(3):542-556.e9. PubMed Pilkinton MA, et al. 2017. Vaccine. 35:329. PubMed Lee J, et al. 2015. Clin Immunol. 159: 37-46. PubMed RY H, et al. 2016. Oncoimmunology. 6:e1249561. PubMed Bradley T, et al. 2020. Nat Commun. 11:948. PubMed Horn C, et al. 2021. HIV Med. 22:397. PubMed Zebley CC, et al. 2021. Cell Rep. 37:110079. PubMed Gannon PO, et al. 2020. Cytotherapy. 22(12):780-791. PubMed de Jonge K, et al. 2021. OncoImmunology. 10(1):1873585. PubMed Bhattacharya P, et al. 2020. Elife. 9:00. PubMed Han Q, et al. 2020. Cell Rep. 30:1553. PubMed Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed Leng T, et al. 2019. Cell Rep. 28:3077. PubMed Levin MJ, et al. 2018. J Clin Invest. 128:4429. PubMed Sam J, et al. 2020. Front Oncol. 10:575737. PubMed Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed Collinson–Pautz MR, et al. 2019. Leukemia. 33:2195. PubMed Karlsson J, et al. 2020. Nat Commun. 1.773611111. PubMed Claiborne D, et al. 2015. Proc Natl Acad Sci U S A. 112:1480. PubMed Riberdy JM, et al. 2020. Mol Ther Methods Clin Dev. 1.146527778. PubMed Suzuki S, et al. 2020. Cancer Sci. 1943:111. PubMed Nicholas K, et al. 2015. Cytometry A. 10.1002/cyto.a.22799. PubMed Paris R, et al. 2015. PLoS One. 10: 0144767. PubMed Kim N, et al. 2020. Nat Commun. 2.045138889. PubMed Guéguen P, et al. 2021. Sci Immunol. 6:. PubMed
RRID: AB_10900818 (BioLegend Cat. No. 329919) AB_10960742 (BioLegend Cat. No. 329920)
Structure: Immunoglobulin superfamily
Distribution: Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells
Ligand/Receptor: B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Gene ID: 5133
UniProt: View information about CD279 on UniProt.org
Clone: EH12.2H7
Regulatory Status: RUO
Other Names: PD-1, PDCD1
Isotype: Mouse IgG1, κ
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.